Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes.
The next generation of anxiolytics may be subtype-selective partial agonists at GABA-A receptors. By exploiting new psychopharmacologic principles, such as the targeting of receptor subtypes that have unique subunits and the partial activation of these subtypes with stabilizers, we may eventually have anxiolytics that are rapid acting, but without sedation, amnesia, or dependence.
Stahl
Stephen M
SM
Neuroscience Education Institute in Carlsbad, Calif. 92009, USA.
D000081:Acetamides / Q000494:pharmacology; D000647:Amnesia / Q000139:chemically induced; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001007:Anxiety / Q000188:drug therapy* / Q000378:metabolism; D018755:GABA Agonists / Q000494:pharmacology*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects; D011725:Pyridines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000187:drug effects*; D012890:Sleep / Q000187:drug effects*; D000077334:Zolpidem
D000081:Acetamides; D014151:Anti-Anxiety Agents; D018755:GABA Agonists; D006993:Hypnotics and Sedatives; D011725:Pyridines; D011743:Pyrimidines; D011963:Receptors, GABA-A; D000077334:Zolpidem; C085665:zaleplon